MedPath

SpO2 Accuracy In Vivo Testing for Neonates & Infants

Not Applicable
Withdrawn
Conditions
Pulse Oximetry
Interventions
Device: Reference CO-oximetry sensor
Device: MEDLINE RENEWAL PULSE OXIMETRY SENSORS
Registration Number
NCT03843489
Lead Sponsor
Medline Industries
Brief Summary

The purpose of this clinical study is to validate the oxygen saturation (SpO2) accuracy of various pulse oximetry systems and sensors (new designs and/or reprocessed) during non-motion conditions as compared to arterial blood samples, drawn in the normal course of patient care, assessed by CO-Oximetry in neonates and infants. The primary end goal is to provide supporting documentation for the SpO2 accuracy of these pulse oximetry systems. The secondary end goal is to provide data for evaluation of clinical impact of measured to calculated SaO2 and related issues.

Detailed Description

FDA Guidance for pulse oximeters (March 4, 2013), section 4.1.2, In vivo testing for SpO2 accuracy for neonates, calls for the devices to be first tested in adults during hypoxia tests with arterial samples compared to measured oxygen saturation. This has been previously completed on the devices that will be tested in this protocol. In order to verify safe clinical performance in the neonate, the FDA then requires testing using neonatal arterial samples that are collected in the normal course of care; which is the primary purpose of this protocol. As a secondary purpose the data will be utilized to evaluate the impact of calculated oxygen saturation versus measured oxygen saturation and related issues.

Neonates/infants who will have an arterial line or sheath placed in the normal course of care will be included in this study. The pulse oximeter sensor must be placed on the Neonates/infant's foot or hand. Neonates who either have repaired PDA but are having the placement of the sensor on the foot (which will be arterial blood only) will be allowed as long as other inclusion/exclusion criteria are met.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Neonates/Infants up to 28 days old
  • Neonates/Infants less than 5kg.

And one of the following:

Without PDA With a PDA with R-L shunting that will be repaired before arterial samples are taken

Exclusion Criteria
  • Physical malformation of feet or toes or other sensor sites which would limit the ability to place the sensors for the study.
  • Neonates/Infants older than 28 days old.
  • Neonates/Infants outside the weight range for the sensor (Greater than 5kg.)
  • Neonates/Infants with unrepaired PDA. with PDA with R-L shunting
  • Subjects who are undergoing bilirubin light therapy while samples are being obtained.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Reference CO-oximetry sensorReference CO-oximetry sensorA whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
MEDLINE RENEWAL PULSE OXIMETRY SENSORSMEDLINE RENEWAL PULSE OXIMETRY SENSORSReference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
Primary Outcome Measures
NameTimeMethod
Validation of SpO2 accuracy of pulse oximetry sensors4 hours

To validate SpO2 accuracy performance of Sponsor sensors by an Accuracy Root Mean Square (Arms) value. Reference CO-Oximetry will be used as the basis for comparison for the investigational device SpO2 readings.

Secondary Outcome Measures
NameTimeMethod
Calculated oxygen saturation versus measured oxygen saturation4 hours

The arterial sample will always be measured in the reference co-oximeter. The sample may also be measured in the currently used AVOX 1000E.

Trial Locations

Locations (1)

Children's Hospital Colorado

🇺🇸

Aurora, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath